The metered dose inhaler devices market size has grown strongly in recent years. It will grow from $16.23 billion in 2025 to $17.12 billion in 2026 at a compound annual growth rate (CAGR) of 5.5%. The growth in the historic period can be attributed to rising asthma prevalence, increasing COPD incidence, widespread use of inhalation therapy, physician preference for mdIs, availability of generic inhalers.
The metered dose inhaler devices market size is expected to see strong growth in the next few years. It will grow to $21.06 billion in 2030 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to growth of smart inhalers, environmental regulations on propellants, homecare treatment expansion, digital adherence monitoring demand, emerging respiratory therapies. Major trends in the forecast period include smart dose tracking inhalers, breath-actuated inhalation technology, compact and portable device designs, dose accuracy enhancement, eco-friendly propellant adoption.
The growing prevalence of chronic obstructive pulmonary diseases (COPD) is expected to drive the expansion of the metered dose inhaler (MDI) devices market. COPD is a progressive lung condition marked by airflow restriction, usually caused by prolonged exposure to irritants such as cigarette smoke, and leads to symptoms such as shortness of breath, coughing, and wheezing. The rise in COPD cases can be attributed to factors such as tobacco consumption, air pollution, an aging population, and delayed diagnosis or treatment. MDI devices are vital in managing COPD by delivering medication directly to the lungs, offering rapid relief and improving airflow. For example, in December 2023, the National Institutes of Health, a US-based government agency, projected that COPD cases would increase from 532 million in 2030 to 592 million by 2050. Consequently, the growing prevalence of COPD is fueling the demand for metered dose inhaler devices.
The increasing levels of air pollution are expected to drive the growth of the metered dose inhaler (MDI) devices market in the coming years. Air pollution refers to the presence of harmful substances in the atmosphere, including particulate matter, gases, and biological molecules, which can lead to adverse health effects. Exposure to air pollution is a significant risk factor for respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). The rise in air pollution is primarily attributed to industrialization, urbanization, growing vehicular emissions, and the combustion of fossil fuels. MDIs play a vital role in supporting public health by delivering targeted medication to manage respiratory disorders that are triggered or aggravated by polluted air. For example, in October 2025, according to the Clean Air Fund, a UK-based nonprofit philanthropic organization, funding for fossil fuel-related projects increased by 80% in 2023, rising from $5.3 billion to $9.5 billion, contributing to worsening air pollution. Additionally, fossil fuel combustion is responsible for more than 5 million of the 8.1 million premature deaths annually linked to air pollution. Therefore, rising air pollution is fueling the growth of the metered dose inhaler devices market.
Leading companies in the metered dose inhaler devices market are concentrating on developing advanced technologies, such as pressurized metered dose inhalers (pMDIs), to boost medication delivery efficiency and increase patient adherence. pMDIs are devices that release a specific dose of medication in aerosol form using a pressurized propellant. For example, in July 2023, Lupin Limited, an India-based pharmaceutical company, introduced Luforbec 100/6, a pMDI aimed at treating adult asthma and chronic obstructive pulmonary disease (COPD) in Germany. This inhaler combines 100 µg of beclometasone and 6 µg of formoterol, offering an effective combination therapy for patients. Notably, Luforbec is priced around 47% below the fixed reference price, making it more affordable. Given that approximately 5% of adults in Germany suffer from asthma, this launch highlights Lupin's dedication to meeting significant healthcare demands and improving respiratory care outcomes.
Major companies operating in the metered dose inhaler devices market are Pfizer Inc., Merck & Co. Inc., AstraZeneca PLC, GlaxoSmithKline plc, 3M Company, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., Berry Global Inc., AptarGroup Inc., Philips Healthcare, Chiesi Farmaceutici S.p.A., Cipla Limited, Gerresheimer AG, Zydus Lifesciences Limited, Mylan N.V., Nemera, Beximco Pharmaceuticals Limited, Cohero Health Inc., Bespak Europe Ltd., Trudell Medical International, Iconovo AB.
North America was the largest region in the metered dose inhaler devices market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the metered dose inhaler devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the metered dose inhaler devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the metered dose inhaler devices market by increasing costs of imported valves, canisters, and electronic components used in smart inhalers. Portable and smart MDI segments are most affected, particularly in North America and Europe due to reliance on Asia-Pacific manufacturing hubs such as China. These tariffs have raised device pricing and supply costs, but they have also encouraged local manufacturing, innovation in sustainable propellants, and regional sourcing strategies.
The metered dose inhaler devices market research report is one of a series of new reports that provides metered dose inhaler devices market statistics, including metered dose inhaler devices industry global market size, regional shares, competitors with a metered dose inhaler devices market share, detailed metered dose inhaler devices market segments, market trends and opportunities, and any further data you may need to thrive in the metered dose inhaler devices industry. This metered dose inhaler devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Metered dose inhalers (MDIs) are medical devices that deliver a specific amount of aerosolized medication directly into the lungs through inhalation. These inhalers are widely used to manage respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), and various other lung diseases.
There are several types of metered dose inhaler devices, including desktop metered dose inhalers, portable metered dose inhalers, and others. Desktop metered dose inhalers are fixed devices primarily found in clinical environments, providing a controlled dose of aerosolized medication. These devices are available through both online and offline distribution channels and are commonly used for conditions such as asthma and COPD. They serve a range of end users, including hospitals, clinics, homecare settings, and more.
The metered dose inhaler devices market consists of sales of products including bronchodilators, corticosteroids, combination inhalers, and anticholinergics. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The metered dose inhaler devices market size is expected to see strong growth in the next few years. It will grow to $21.06 billion in 2030 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to growth of smart inhalers, environmental regulations on propellants, homecare treatment expansion, digital adherence monitoring demand, emerging respiratory therapies. Major trends in the forecast period include smart dose tracking inhalers, breath-actuated inhalation technology, compact and portable device designs, dose accuracy enhancement, eco-friendly propellant adoption.
The growing prevalence of chronic obstructive pulmonary diseases (COPD) is expected to drive the expansion of the metered dose inhaler (MDI) devices market. COPD is a progressive lung condition marked by airflow restriction, usually caused by prolonged exposure to irritants such as cigarette smoke, and leads to symptoms such as shortness of breath, coughing, and wheezing. The rise in COPD cases can be attributed to factors such as tobacco consumption, air pollution, an aging population, and delayed diagnosis or treatment. MDI devices are vital in managing COPD by delivering medication directly to the lungs, offering rapid relief and improving airflow. For example, in December 2023, the National Institutes of Health, a US-based government agency, projected that COPD cases would increase from 532 million in 2030 to 592 million by 2050. Consequently, the growing prevalence of COPD is fueling the demand for metered dose inhaler devices.
The increasing levels of air pollution are expected to drive the growth of the metered dose inhaler (MDI) devices market in the coming years. Air pollution refers to the presence of harmful substances in the atmosphere, including particulate matter, gases, and biological molecules, which can lead to adverse health effects. Exposure to air pollution is a significant risk factor for respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). The rise in air pollution is primarily attributed to industrialization, urbanization, growing vehicular emissions, and the combustion of fossil fuels. MDIs play a vital role in supporting public health by delivering targeted medication to manage respiratory disorders that are triggered or aggravated by polluted air. For example, in October 2025, according to the Clean Air Fund, a UK-based nonprofit philanthropic organization, funding for fossil fuel-related projects increased by 80% in 2023, rising from $5.3 billion to $9.5 billion, contributing to worsening air pollution. Additionally, fossil fuel combustion is responsible for more than 5 million of the 8.1 million premature deaths annually linked to air pollution. Therefore, rising air pollution is fueling the growth of the metered dose inhaler devices market.
Leading companies in the metered dose inhaler devices market are concentrating on developing advanced technologies, such as pressurized metered dose inhalers (pMDIs), to boost medication delivery efficiency and increase patient adherence. pMDIs are devices that release a specific dose of medication in aerosol form using a pressurized propellant. For example, in July 2023, Lupin Limited, an India-based pharmaceutical company, introduced Luforbec 100/6, a pMDI aimed at treating adult asthma and chronic obstructive pulmonary disease (COPD) in Germany. This inhaler combines 100 µg of beclometasone and 6 µg of formoterol, offering an effective combination therapy for patients. Notably, Luforbec is priced around 47% below the fixed reference price, making it more affordable. Given that approximately 5% of adults in Germany suffer from asthma, this launch highlights Lupin's dedication to meeting significant healthcare demands and improving respiratory care outcomes.
Major companies operating in the metered dose inhaler devices market are Pfizer Inc., Merck & Co. Inc., AstraZeneca PLC, GlaxoSmithKline plc, 3M Company, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., Berry Global Inc., AptarGroup Inc., Philips Healthcare, Chiesi Farmaceutici S.p.A., Cipla Limited, Gerresheimer AG, Zydus Lifesciences Limited, Mylan N.V., Nemera, Beximco Pharmaceuticals Limited, Cohero Health Inc., Bespak Europe Ltd., Trudell Medical International, Iconovo AB.
North America was the largest region in the metered dose inhaler devices market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the metered dose inhaler devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the metered dose inhaler devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the metered dose inhaler devices market by increasing costs of imported valves, canisters, and electronic components used in smart inhalers. Portable and smart MDI segments are most affected, particularly in North America and Europe due to reliance on Asia-Pacific manufacturing hubs such as China. These tariffs have raised device pricing and supply costs, but they have also encouraged local manufacturing, innovation in sustainable propellants, and regional sourcing strategies.
The metered dose inhaler devices market research report is one of a series of new reports that provides metered dose inhaler devices market statistics, including metered dose inhaler devices industry global market size, regional shares, competitors with a metered dose inhaler devices market share, detailed metered dose inhaler devices market segments, market trends and opportunities, and any further data you may need to thrive in the metered dose inhaler devices industry. This metered dose inhaler devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Metered dose inhalers (MDIs) are medical devices that deliver a specific amount of aerosolized medication directly into the lungs through inhalation. These inhalers are widely used to manage respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), and various other lung diseases.
There are several types of metered dose inhaler devices, including desktop metered dose inhalers, portable metered dose inhalers, and others. Desktop metered dose inhalers are fixed devices primarily found in clinical environments, providing a controlled dose of aerosolized medication. These devices are available through both online and offline distribution channels and are commonly used for conditions such as asthma and COPD. They serve a range of end users, including hospitals, clinics, homecare settings, and more.
The metered dose inhaler devices market consists of sales of products including bronchodilators, corticosteroids, combination inhalers, and anticholinergics. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Metered Dose Inhaler Devices Market Characteristics
3. Metered Dose Inhaler Devices Market Supply Chain Analysis
4. Global Metered Dose Inhaler Devices Market Trends and Strategies
5. Metered Dose Inhaler Devices Market Analysis of End Use Industries
7. Global Metered Dose Inhaler Devices Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Metered Dose Inhaler Devices Total Addressable Market (TAM) Analysis for the Market
9. Metered Dose Inhaler Devices Market Segmentation
10. Metered Dose Inhaler Devices Market Regional and Country Analysis
11. Asia-Pacific Metered Dose Inhaler Devices Market
12. China Metered Dose Inhaler Devices Market
13. India Metered Dose Inhaler Devices Market
14. Japan Metered Dose Inhaler Devices Market
15. Australia Metered Dose Inhaler Devices Market
16. Indonesia Metered Dose Inhaler Devices Market
17. South Korea Metered Dose Inhaler Devices Market
18. Taiwan Metered Dose Inhaler Devices Market
19. South East Asia Metered Dose Inhaler Devices Market
20. Western Europe Metered Dose Inhaler Devices Market
21. UK Metered Dose Inhaler Devices Market
22. Germany Metered Dose Inhaler Devices Market
23. France Metered Dose Inhaler Devices Market
24. Italy Metered Dose Inhaler Devices Market
25. Spain Metered Dose Inhaler Devices Market
26. Eastern Europe Metered Dose Inhaler Devices Market
27. Russia Metered Dose Inhaler Devices Market
28. North America Metered Dose Inhaler Devices Market
29. USA Metered Dose Inhaler Devices Market
30. Canada Metered Dose Inhaler Devices Market
31. South America Metered Dose Inhaler Devices Market
32. Brazil Metered Dose Inhaler Devices Market
33. Middle East Metered Dose Inhaler Devices Market
34. Africa Metered Dose Inhaler Devices Market
36. Metered Dose Inhaler Devices Market Competitive Landscape and Company Profiles
37. Metered Dose Inhaler Devices Market Other Major and Innovative Companies
40. Metered Dose Inhaler Devices Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Metered Dose Inhaler Devices Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses metered dose inhaler devices market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for metered dose inhaler devices? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The metered dose inhaler devices market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type: Desktop Metered Dose Inhaler Devices; Portable Metered Dose Inhaler Devices; Other Types2) By Distribution Channel: Online; Offline
3) By Application: Asthma; Chronic Obstructive Pulmonary Disease; Other Applications
4) By End-User: Hospitals; Clinics; Homecare Settings; Other End Users
Subsegments:
1) By Desktop Metered Dose Inhaler Devices: Standard desktop MDI devices; High-performance desktop MDI devices; Smart desktop MDI devices2) By Portable Metered Dose Inhaler Devices: Conventional portable MDI devices; Advanced portable MDI devices; Smart portable MDI devices
3) By Other Types: Nebulizer-Based MDI devices; Dry powder inhaler (DPI) combined devices; Soft mist inhaler (SMI) devices; Other specialized MDI devices
Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; AstraZeneca PLC; GlaxoSmithKline plc; 3M Company; Boehringer Ingelheim GmbH; Teva Pharmaceutical Industries Ltd.; Berry Global Inc.; AptarGroup Inc.; Philips Healthcare; Chiesi Farmaceutici S.p.A.; Cipla Limited; Gerresheimer AG; Zydus Lifesciences Limited; Mylan N.V.; Nemera; Beximco Pharmaceuticals Limited; Cohero Health Inc.; Bespak Europe Ltd.; Trudell Medical International; Iconovo AB
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Metered Dose Inhaler Devices market report include:- Pfizer Inc.
- Merck & Co. Inc.
- AstraZeneca PLC
- GlaxoSmithKline plc
- 3M Company
- Boehringer Ingelheim GmbH
- Teva Pharmaceutical Industries Ltd.
- Berry Global Inc.
- AptarGroup Inc.
- Philips Healthcare
- Chiesi Farmaceutici S.p.A.
- Cipla Limited
- Gerresheimer AG
- Zydus Lifesciences Limited
- Mylan N.V.
- Nemera
- Beximco Pharmaceuticals Limited
- Cohero Health Inc.
- Bespak Europe Ltd.
- Trudell Medical International
- Iconovo AB
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 17.12 Billion |
| Forecasted Market Value ( USD | $ 21.06 Billion |
| Compound Annual Growth Rate | 5.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 22 |
